It has been 13 years since the International Council of Medical Journal Editors (ICMJE) issued a statement requiring the prospective registration of clinical trials (CT) as a condition for publication in a biomedical journal ([@B1]). While CT registries have been in place for at least five decades, no public and comprehensive international registry platform was available before the ICMJE mandate ([@B2] -- [@B4]). In 2004, the Mexico Global Forum and Ministerial Summit on Health Research addressed the vital role of research in the improvement and sustainable development of population health, with a specific emphasis on how to translate knowledge into action to improve health. A global CT registry was deemed as a vital mechanism to enhance the capacity to generate and disseminate knowledge and create "a network of international clinical trials registers to ensure a single point of access and the unambiguous identification of trials" ([@B5]). In May 2006, the WHO International Clinical Trial Registry Platform (ICTRP) was developed following the Summit\'s discussions of clinical trials transparency in health research and narrowing the disparities in health systems performance between developing and developed countries ([@B6]).

At present, the ICTRP forms a network comprising 16 existing Primary Registries and the ClinicalTrials.gov database (National Library of Medicine, Bethesda, MD, United States), all of which meet the WHO Registry Criteria or that are working with ICTRP towards becoming a Primary Registry. The ICTRP also provides a unique Universal Trial Number (UTN) to facilitate the explicit identification of CT.

In the last 10 years, the number of registered clinical trials has been increasing worldwide. To date (January 2017), the ICTRP has more than 340 000 clinical trials in over 175 countries. Registries in Latin America, including the Brazilian registry of clinical trials (ReBEC), the Cuban registry of clinical trials (RPCEC), and the Peruvian registry of clinical trials (CENCEC) contribute data to the ICTRP ([@B7]).

The CT registration initiative is an attempt by the scientific community to improve transparency and public confidence in the conduct of research, to minimize publication and reporting bias, and to give visibility to the entire investigation process. Although publication bias and selective reporting remain widespread ([@B8]--[@B10]), the ICTRP has enabled the more extensive identification of clinical research. Van Enst and colleagues ([@B11]) stated that searching for additional trials in prospective trial registers when conducting a Cochrane systematic review could reduce this problem. The Cochrane Collaboration Handbook now recommends searching the ICTRP to identify ongoing trials when conducting a systematic review ([@B12]). Additionally, Scherer and colleagues found that Randomized Clinical Trial design methods not reported in conference abstracts are frequently available in the ClinicalTrials.gov registry ([@B13]).

While adherence to trial registration has increased in recent years, it is still difficult to get an accurate measurement. Some studies have been monitoring the prevalence of trial registration among published studies ([@B14]).

The objective of this study was to determine the prevalence of clinical trial registration with the ICTRP and to identify the key characteristics that lead to prospective and retrospective registration in Latin America and the Caribbean.

MATERIALS AND METHODS
=====================

A cross-sectional study identified published, clinical trial studies from Latin America and the Caribbean through a search of PubMed (U.S. National Library of Medicine, Bethesda, Maryland, United States), LILACS (Latin American and Caribbean Center on Health Sciences Information, PAHO/WHO, São Paulo, Brazil), and the CENTRAL (Cochrane Central Register of Controlled Trials, The Cochrane Collaboration, London, United Kingdom). Studies were included if published on 1 January -- 31 December 2015, at least one author was affiliated with at least one LAC country, the clinical trial was conducted in at least one LAC site, and the full text of the article was available (see Supplementary Materials for more details). To find any additional studies, a manual search was performed on the reference lists of retrieved, relevant articles.

A sample of references was randomly selected using a random number sequence generator by nosetup.org, an open access website. The titles and abstracts of these articles were verified before inclusion. Duplicated articles and those that did not meet inclusion criteria were excluded from the analysis. Data were extracted from full-text manuscripts into the data template. Extracted data included: reference, first author\'s country affiliation, and if the article was registered in an international CT registry recognized by the ICTRP network. Each registered CT was searched via the ICTRP search portal (<http://apps.who.int/trialsearch/>) to assess if the study was prospectively or retrospectively registered.

Trial registration terms were defined as follows:

-   Trial start date: date of the first patient visit.

-   Trial registration date: date on which the study information was submitted to the trial registry.

-   Prospectively registered: the trial start date (actual/anticipated) is the same or after trial registration date.

-   Retrospectively registered: the trial start date (actual/anticipated) is prior to the trial registration date.

Additional information was extracted, including language, contact email, duration of the study and follow up, purpose of intervention, use of alternative therapy, trial phase, randomization, disease / condition studied, neglected disease as a topic, target sample size, gender, presence of children, pregnant women or other vulnerable populations, blinding, recruitment status, countries of recruitment, whether it was multinational or multicenter, approval of the ethics committee, and agreement consent. The main funding source of CT was categorized as "public," "private," "self-funded," or "not reported." An Internet search of funding sources was conducted to avoid misclassification. Trials were categorized according to trial registration status (registered or unregistered) and relative date (prospectively or retrospectively registered).

All the statistical analysis was performed with a significance (alpha) level of 0.05. Chi-square statistics and 2-tailed Fisher exact tests were used to examine the significance of the association between categorical variables. Multivariate Logistic Regression Models was used to compute the β coefficients for known factors for trial registration. To develop a good-fit model, all significant variables derived from univariate analysis were entered into the model. Variables significant at 5% were included in the model using stepwise backward elimination, with trial registration as the dependent variable. The statistical analysis was done using the IBM SPSS^®^ Statistics software, version 17 (SPSS Inc., an IBM company, Chicago, Illinois, United States).

RESULTS
=======

Baseline characteristics of clinical trials
-------------------------------------------

The database search returned 1 502 results, from which 410 references were randomly selected and screened against the inclusion criteria. Of these, 113 references were excluded, mostly because they were not CT or were not conducted in a LAC country. The resulting 297 articles were included in the analysis (see Supplementary Materials for more details). Most of these articles were full-text publications, but 11 protocols and 3 posters were also included. Approximately 303 763 participants were recruited across all included trials. English was the dominant publication language of the included articles (90.9%), followed by Spanish (5.4%) and Portuguese (3.7%).

The affiliations of the publications were diverse and 107 (36%) had multinational authors\' affiliations. Although study authors were affiliated with 16 LAC countries, approximately 90% of publications were from just five: Argentina, Brazil, Chile, Cuba, and Mexico (see Supplementary Materials for more details). Around 76.8% of articles had a first author with an LAC affiliation. When first authors were not affiliated with a LAC country (23.2%), they tended to be from the United States (8.1%), the United Kingdom (2.4%), Australia (2%), Canada (2%), or other countries (5.4%). Over one-third (36.7%) of the clinical trials were multicenter and almost one-quarter (23.9%) were multinational. Overall, 32.7% of CT had private sponsors, 34.7% were publicly sponsored, 2% were self-funded, and 30.6% did not report their funding source. Although the proportion of CT funded by the private sector was higher than that funded by the public sector in most countries, in Brazil nearly 58% were funded by the public sector.

The majority (71.7%) of CT were related to treatment, while 17.2% were related to prevention, 3.7% to disease diagnosis, and 7.4% to others. About 16.5% of CT were phase 1 or phase 2 trials, 27.3% were phase 3 or phase 4 trials, and the vast majority (56.2%) did not specify a phase. In addition, the majority of CT were randomized (85.2%) and blinded (52.5%).

Information on the recruitment of vulnerable participants, such as children, pregnant women, or other vulnerable populations (i.e., indigenous) was actively searched. Of the total, 52 trials (17.5%) recruited children or pregnant women, 38 recruited children, 13 recruited women, and 1 recruited both pregnant women and children. None of the trials declared enrollment of other vulnerable populations, and 6 did not provide enough information to determine whether vulnerable participants of any kind had been included. Only 9 trials (3%) studied neglected diseases.

In addition, ethical characteristics of the CT were considered. In all, 223 (75.1%) of the trials reported the approval of an ethics committee and 236 (79.5%) reported the collection of an informed consent. Only 204 (68.7%) included both ethical requirements.

Most of the articles (77.1%) were CT having 1-year or less follow up; 11.8% had a follow up at 2 years or more. [Table 1](#t1){ref-type="table"} shows information related to other characteristics of the included trials.

###### Descriptive characteristics of studies (n = 297) included in a review of adherence to clinical trial registration in countries of Latin America and the Caribbean, 2015

  Characteristic                                                                        Studies (*n* = 297)[a](#TFN1){ref-type="table-fn"}         
  ------------------------------------------------------------------------------------- ---------------------------------------------------- ----- ------
  Affiliation in a country with a primary registry in the WHO Registry Network                                                                     
                                                                                        Yes[b](#TFN2){ref-type="table-fn"}                   200   67.3
                                                                                        No                                                   97    32.7
  Multinational                                                                                                                                    
                                                                                        Yes                                                  71    23.9
                                                                                        No                                                   224   75.4
                                                                                        Unclear                                              2     0.7
  Multicenter                                                                                                                                      
                                                                                        Yes                                                  109   36.7
                                                                                        No                                                   118   39.7
                                                                                        Unclear                                              70    23.6
  Phase of study                                                                                                                                   
                                                                                        Early (Phase 1-2)                                    49    16.5
                                                                                        Late (Phase 3-4)                                     81    27.3
                                                                                        Unclear                                              167   56.2
  Randomization                                                                                                                                    
                                                                                        Yes                                                  253   85.2
                                                                                        No                                                   36    12.1
                                                                                        Unclear                                              8     2.7
  Blinding                                                                                                                                         
                                                                                        Yes                                                  156   52.5
                                                                                        No                                                   90    30.3
                                                                                        Unclear                                              51    17.2
  Clinical trials related to alternative therapies[c](#TFN3){ref-type="table-fn"}                                                                  
                                                                                        Yes                                                  45    15.2
                                                                                        No                                                   252   84.9
  Recruitment of vulnerable participants (e.g., children, pregnant women, indigenous)                                                              
                                                                                        Yes[d](#TFN4){ref-type="table-fn"}                   52    17.5
                                                                                        No                                                   239   80.5
                                                                                        Not reported                                         6     2.0

Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.

Only Brazil and Cuba had primary registries in the WHO Registry Network in 2015.

Alternative therapies where classified using Merriam-Webster\'s Dictionary definition.

Total trials recruiting any vulnerable population is 52: 38 trials recruited only children; 13 only pregnant women; and 1, both children and pregnant women.

Source

: Prepared by the authors from the study results.

Trial registration
------------------

[Table 2](#t2){ref-type="table"} shows characteristics of all 297 clinical trials considered for review, according to registration status (registered or not registered). [Table 3](#t3){ref-type="table"} shows characteristics of the 178 registered trials, according to their prospective or retrospective status. Both tables include categorical variables, including the phase of the study, randomization, binding, alternative therapy, funding source, ethical considerations, and follow-up duration. *P*-values associated with each categorical variable in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"} are based on the chi-squared test for homogeneity with a significance (alpha) level of 0.05.

###### Characteristics of clinical trials included in a study of adherence to clinical trial registration in countries of Latin America and the Caribbean, according to registration status (*n* = 297),[a](#TFN6){ref-type="table-fn"} 2015

  Characteristic                                                                                              Registered (*n* = 178)[a](#TFN6){ref-type="table-fn"}              Not registered (*n* = 119)[a](#TFN6){ref-type="table-fn"}         *P*[b](#TFN7){ref-type="table-fn"}   
  ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------- ----------------------------------------------------------- ----- ------------------------------------ --
  Affiliation in a country with primary registry in the WHO Registry Network[c](#TFN8){ref-type="table-fn"}                                                                                                                                        0.025                                
                                                                                                              Yes                                                     111        62.4                                                        89    74.8                                 
                                                                                                              No                                                      67         37.6                                                        30    25.2                                 
  Multinational                                                                                                                                                                                                                                    \< 0.001                             
                                                                                                              Yes                                                     67         37.9                                                        4     3.4                                  
                                                                                                              No                                                      110        62.1                                                        113   95.0                                 
                                                                                                              Unclear [d](#TFN9){ref-type="table-fn"}                 0          0                                                           2     1.7                                  
  Multicenter                                                                                                                                                                                                                                      \< 0.001                             
                                                                                                              Yes                                                     90         50.6                                                        19    16.0                                 
                                                                                                              No                                                      55         30.9                                                        63    52.9                                 
                                                                                                              Unclear[d](#TFN9){ref-type="table-fn"}                  33         18.5                                                        37    31.1                                 
  Phase of study                                                                                                                                                                                                                                   \< 0.001                             
                                                                                                              Early (phase 1-2)                                       34         19.1                                                        15    12.6                                 
                                                                                                              Late (phase 3-4)                                        79         44.4                                                        2     1.7                                  
                                                                                                              Unclear[d](#TFN9){ref-type="table-fn"}                  65         36.5                                                        102   85.7                                 
  Randomization                                                                                                                                                       \< 0.001                                                                                                          
                                                                                                              Yes                                                     164        92.1                                                        89    74.8                                 
                                                                                                              No                                                      12         6.7                                                         24    20.2                                 
                                                                                                              Unclear[d](#TFN9){ref-type="table-fn"}                  2          1.1                                                         6     5.9                                  
  Blinding                                                                                                                                                                                                                                         \< 0.001                             
                                                                                                              Yes                                                     115        64.6                                                        41    34.5                                 
                                                                                                              No                                                      58         32.6                                                        32    26.9                                 
                                                                                                              Unclear[d](#TFN9){ref-type="table-fn"}                  5          2.8                                                         46    38.7                                 
  Clinical trials related to alternative therapies [e](#TFN10){ref-type="table-fn"}                                                                                                                                                                \< 0.002                             
                                                                                                              Yes                                                     21         11.8                                                        24    20.2                                 
                                                                                                              No                                                      157        88.2                                                        95    79.8                                 
  Study of a neglected disease                                                                                                                                                                                                                     0.267                                
                                                                                                              Yes                                                     7          3.9                                                         2     1.7                                  
                                                                                                              No                                                      171        96.1                                                        117   98.3                                 
  Funding source                                                                                                                                                                                                                                   \< 0.001                             
                                                                                                              Private                                                 84         47.2                                                        13    10.9                                 
                                                                                                              Public                                                  76         42.7                                                        27    22.7                                 
                                                                                                              Self                                                    1          0.05                                                        5     4.2                                  
                                                                                                              Not reported[d](#TFN9){ref-type="table-fn"}             17         9.6                                                         74    62.2                                 
  Recruitment of vulnerable participants (e.g., children, pregnant women, indigenous)                                                                                                                                                              0.219                                
                                                                                                              Yes                                                     35         19.7                                                        17    14.3                                 
                                                                                                              No                                                      141        79.2                                                        98    82.4                                 
                                                                                                              Not reported[d](#TFN9){ref-type="table-fn"}             2          1.1                                                         4     3.4                                  
  Ethical approval                                                                                                                                                                                                                                 \< 0.001                             
                                                                                                              Yes                                                     122        68.5                                                        101   84.9                                 
                                                                                                              Not reported                                            56         31.5                                                        18    15.1                                 
  Informed consent                                                                                                                                                                                                                                 0.193                                
                                                                                                              Yes                                                     137        77                                                          99    83.2                                 
                                                                                                              Not reported                                            41         23                                                          20                                         
  Approval + consent                                                                                                                                                                                                                               0.009                                
                                                                                                              Yes                                                     112        62.9                                                        92    77.3                                 
                                                                                                              Not reported                                            66         37.1                                                        27    22.7                                 
  Follow up duration                                                                                                                                                                                                                               \< 0.001                             
                                                                                                              Less than 1 Year                                        122        68.5                                                        107   89.9                                 
                                                                                                              1 -- 2 years                                            23         12.9                                                        3     2.5                                  
                                                                                                              More than 2 Years                                       33         18.5                                                        2     1.7                                  
                                                                                                              Unclear[d](#TFN9){ref-type="table-fn"}                  0          0                                                           7     5.9                                  

Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.

*P*-value for the chi-squared or Pearson\'s exact test.

Only Brazil and Cuba had Primary Registry in the WHO Registry Network in 2015.

This level of the categorical variable was not included in the calculations for *P*-value, even though the relative percentages are presented in this table.

Alternative therapies were classified using Merriam-Webster\'s Dictionary definition.

Source

: Prepared by the authors from the study results.

###### Association between some characteristics of clinical trials and registration status (independent variable) using a multivariate model, (*n* = 297)^a^ in a study of adherence to clinical trial registration in countries of Latin America and the Caribbean, 2015

  Characteristic                                                               Odds Ratio (OR)        95% Confidence Interval (95%CI)   *P* value       Adjusted OR   95%CI   *P* value       
  ---------------------------------------------------------------------------- ---------------------- --------------------------------- --------------- ------------- ------- --------------- ----------
  Affiliation in a country with primary registry in the WHO Registry Network                                                                                                                  
                                                                               No                                                       Reference                             Reference       
                                                                               Yes                    1.44                              1.1 -- 2.88     0.006         1.99    1.02 -- 2.87    0.051
  Phase of study                                                                                                                                                                              
                                                                               Early (phase 1 -- 2)                                     Reference                             Reference       
                                                                               Late (phase 3 -- 4)    7.81                              3.76 -- 16.23   \< 0.001      8.17    3.28 -- 20.3    \<0.001
  Founding source                                                                                                                                                                             
                                                                               Public                                                   Reference                             Reference       
                                                                               Private                3.43                              1.71 -- 6.84    \< 0.001      1.46    0.65 -- 3.27    0.35
                                                                               Self-founded           0.10                              0.012 -- 0.93   0.044         0.05    0.004 -- 0.60   0.019
                                                                               Not reported           0.10                              0.053 -- 0.22   \< 0.001      0.078   0.032 -- 0.19   \< 0.001
  Multicentric                                                                                                                                                                                
                                                                               No                                                       Reference                             Reference       
                                                                               Yes                    5.42                              2.93 -- 10.01   \< 0.001      3.83    1.63 -- 8.99    0.002
                                                                               Not reported           1.14                              0.42 -- 3.08    0.78          2.41    0.67 -- 8.68    0.176
  Language                                                                                                                                                                                    
                                                                               English                                                  Reference                             Reference       
                                                                               Spanish                0.13                              0.036 -- 0.47   0.002         0.27    0.045 -- 1.66   0.16
                                                                               Portuguese             0.21                              0.055 -- 0.82   0.025         0.16    0.033 -- 0.82   0.029

Source

: Prepared by the authors from the study results.

Of the 297 clinical trials included in the analysis, 178 (59.9%) were registered, 92 of which (51.7%) were retrospective. The majority of the registered trials (84.3%) provided a registration number or link to the registration in the publication; the remainding (15.7%) were found by manually searching the ICTRP.

The highest registration rates were found in Argentina, Brazil, Chile, Cuba, and Mexico. Of trials affiliated with countries that have a WHO-recognized registration platform, only 62.5% were registered; whereas, 37.6% of trials were registered for other countries. In other words, CT affiliated with both countries with a WHO-recognized national registration platform were more likely to be registered. There was also a significant difference in retrospective versus prospective registration rates according to the country affiliation.

It was found that 37.9% of registered CT were multinational, as compared with only 3.4% of unregistered CT (*P* \< 0.001). There was also significant variation in multicenter studies based on registration status: 50.6% of registered CT were multicenter trials, as compared with only 16% of unregistered CT (*P* \< 0.001).

The Clinicaltrials.gov registry was the most frequently used (84.8%), followed by Brazil\'s ReBEC (9.6%), other registries (4.5%), and Cuba\'s RPCEC (1.1%). Only 66.7% of the Cuban and 15.7% of the Brazilian CT used their own national registries (RPCEC and ReBEC, respectively). None of the registrations done outside of the Americas had a non-LAC first author. All of the publications with a first non-LAC author were registered in Clinicaltrials.gov (62; 89.9%), and the remaining (10.1%) were not registered. Overall, most of the registration platforms, such as Clinicaltrials.gov and RPCEC, had retrospective registration rates from 48% -- 62%, but ReBEC had a rate of 82.4%.

Regarding funding, 47.2% of registered trials were privately funded versus only 10.9% of unregistered trials. Only 9.6% of registered trials did not report funding sources, as compared to 62.2% of unregistered trials (*P* \< 0.001). Of multinational trials, 53.6% were privately-funded, 11.7% received exclusively public funds, none were self-funded, 23% had mixed funds, and 7.7% did not report their funding source (*P* \< 0.001). Of CT assessing alternative therapies, only 6.2% were privately funded, 22.3% received public funding, 50% were self-funded, 7.2% had mixed funds, and 14.3% did not report a funding source (*P* \< 0.001).

Registered trials showed greater variation in the follow-up time used to complete the CT as compared to unregistered trials ([Table 2](#t2){ref-type="table"}). There was no statistically significant difference between registered and unregistered trials nor between prospective and retrospective registered trials regarding the study purpose, the study of neglected diseases, and the recruitment of vulnerable study populations ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}). Ethical considerations also did not show a statistically significant difference between prospectively and retrospectively registered trials (see the Supplementary Materials for more details).

Multivariable analyses
----------------------

[Table 3](#t3){ref-type="table"} shows the crude and adjusted (adj) odds ratios (OR), 95% Confidence Intervals (95%CI), and *P*-values for each independent variable. After adjustment, trial registration by phase was found to be significant (*P* \< 0.001); trials in phases 3 -- 4 had 8.17 greater odds of being registered than those in phases 1 -- 2 (adj 95%CI = 3.28 -- 20.32). A significant adjusted association was also seen with funding source; self-funded clinical trials had 0.05 the odds of being registered (adj 95%CI = 0.004 -- 0.60; *P* = 0.019) and clinical trials with unspecified funding sources had 0.078 the odds of being registered (adj 95%CI = 0.032 -- 0.19; *P* \< 0.001), as compared to clinical trials with public funding. Clinical trials that were conducted in multiple study centers had greater odds of being registered than those conducted at a single center (adj OR = 3.83; adj 95%CI = 1.63 -- 8.99; *P* = 0.002). Publication in Portuguese was also significant; clinical trials published in Portuguese had 0.16 the odds of being registered as compared to trials published in English (adj 95%CI = 0.033 -- 0.82; *P* = 0.029).

DISCUSSION
==========

Adherence to trial registration initiatives has improved in recent years. In 2013, the registration rate of randomized controlled trials was only 19.8% ([@B13]), but our study, which followed a similar methodology, found an overall registration rate of 59.9% in 2015. Moreover, among all registered trials, the rate of prospective registration increased from 6.9% to 48.3% in 2013--2015 ([@B14] -- [@B16]). This increase, over a relatively short time period, is a promising trend that may represent the increasing concern for the quality and transparency of clinical trials in LAC countries. In addition, the increase in registration adherence may have already positively impacted results reporting, as multiple recent studies have shown that new research is more likely to be reported ([@B17] -- [@B19]). All studies were conducted using a similar methodology, which provides a basis for a year-by-year comparison.

Previous studies have found that publication rates tend to be higher for CT registered after completion versus those registered prior to completion or with an unknown study status ([@B20]). A possible explanation may be that researchers are retrospectively registering their trials to comply with biomedical journal policies prior to submission for publication. In our study, only 31% of all studies were prospectively registered.

Brazil continues to dominate CT research in LAC. Its CT account for 65% of the total for the region in 2015, though its proportion has decreased slightly from the 70% it held in 2013 ([@B10]). During that same period, CT publication by other LAC nations has increased---perhaps influencing the slight shift.

Although efforts have been made to improve the quality of CT, another prevailing issue is the lack of adequate completeness of registration information ([@B21], [@B22]). Despite the relatively high rate of reporting on ethical considerations and informed consent ([Table 2](#t2){ref-type="table"}), reporting on important information was lacking. For example, funding source, inclusion criteria, and study phase were weakly detailed in many publications. Those incomplete publications tended to be the ones with lower registration rates ([Table 2](#t2){ref-type="table"}). The lack of information related to registration must be addressed as well. Medical journal publications should encourage the publication of the registration number, preferably in the methodology section of the abstract. The vast majority of the registered trials (84.3%) provided a registration number or link to the registration in the publication; the remainder (15.7%) was found by manually searching the ICTRP.

In general, registration adherence tended to be higher among specific groups. For example, trials in phases 3 and 4 represented 44.4% of the registered CT, as compared to just 1.7% of the unregistered (*P* \< 0.001). However, adherence was very low among other groups, such as CT about alternative therapies, which made up 11.8% of the registered CT, but 20.2% of the unregistered (*P* \< 0.001).

The association between funding source and multinational status was analyzed. We found that 53.6% of the privately funded CT were multinational clinical trials as compared with only 11.7% that received public funding; (*P* \< 0.001). We predict that the discrepancies in the association of funding status with multinational study status may be explained by the relatively greater availability of resources available to private sponsors (as compared to public, self, or unspecified funders) that enable privately funded studies to cooperate with international registrations and standards of clinical trials.

As shown in previous studies, privately funded CT are more frequently registered than are publicly funded trials ([@B23], [@B24]). Across all LAC countries, approximately 34% of CT are funded by the public sector. In Brazil, a leader in CT research, an even greater proportion of trials are funded by the public sector. Countries with a large proportion of publicly-funded studies also tend to be the countries with trial registries that form part of the ICTRP network. This may explain our observation that countries with registries within the Network have lower registration rates than those without one. That is, funding source (public versus private) is a confounding factor in the association between having a network-recognized registry and the rate of CT registration. In addition, our observation that publication in Portuguese is significantly associated with low registration rates may also be explained by this confounding phenomenon since Portuguese is the primary language of Brazil.

Policy implications
-------------------

Several steps need to be taken to ensure prospective registration of clinical trials in Latin America and the Caribbean and worldwide ([@B24]). First, the importance of trial registration should be emphasized to all researchers, journal editors, reviewers, and national authorities. All need to further efforts to highlight the value of prospective trial registration, but especially those conducting trials under conditions (i.e., public funding) that have been associated with lower registration rates in the past. Public institutions, especially universities, should provide adequate training and support to researchers to encourage trial registration. In addition, there is a need to address the lack of registration and selective reporting among early phase clinical trials. Lastly, it is imperative that results reporting be addressed; information on methodology, ethical aspects, and source of funding was frequently inadequate.

Limitations
-----------

This study had some limitations. First, the database search was conducted on only three databases and limited to a 1-year period. It was also restricted to published trials; so, completed but unpublished trials would have been overlooked by the search strategy. As a result of these issues, findings may not be representative of all CT published in LAC. Also, some CT may have been missed in the ICTRP when a trial did not have a registration number and did not use keywords. Furthermore, we only had access to what the original researchers published, which may not have been a complete picture of the actual trial or may not have accurately identified the registration as prospective or retrospective.

Due to missing or non-reported information, the quality of the analysis may have been affected. Some variables, such as study type, blinding, and multicenter status, which were missing in as many as 12% of the CT analyzed, may have been a potential source of bias.

Conclusions
===========

While there are still a lot of challenges to overcome, the international registration adherence strategies implemented in recent years have proven to be effective. This study found that the proportion of CT registered in the ICTRP was 59.9 %, of which 51.7% were registered prospectively. Registration adherence and prospective registration have increased in Latin America and the Caribbean, but the proportion of unregistered trials remains high. More effort should be applied to promoting continued improvement in registration rates, regardless of the specific characteristics of the clinical trial.
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